AveXis (AVXS) Posts Wider Q4 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. SPY
4. ATH
5. PTC
6. CME
7. USO
8. AMD
9. EVTL
10. KLC

Go back to AveXis (AVXS) Posts Wider Q4 Loss

AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results

February 27, 2018 4:01 PM EST

On track to request pre-BLA meeting with FDA in Q2 2018 Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of 2018 Anticipates IND submissions for Rett syndrome and genetic ALS in late 2018/early 2019

Conference call and webcast February 27 at 4:30 p.m. EST

CHICAGO, Feb. 27, 2018 (GLOBE NEWSWIRE) --   AveXis, Inc. (NASDAQ: AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the fourth quarter and full... More